Internal Reference Number: FOI_9328
Date Request Received: 02/04/2026 00:00:00
Date Request Replied To: 16/04/2026 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Companies
| Question Number 1: . How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products: 鈥� Abrocitinib 鈥� Acitretin 鈥� Alitretinoin 鈥� Azathioprine 鈥� Baricitinib 鈥� Ciclosporin 鈥� Dupilumab 鈥� Lebrikizumab 鈥� Methotrexate 鈥� Mycophenolate mofetil 鈥� Pimecrolimus 鈥� Phototherapy (UVB or PUVA) - for Atopic Dermatitis only 鈥� Tacrolimus ointment 鈥� Tralokinumab 鈥� Upadacitinib 鈥� Nemolizumab | |
| Answer To Question 1: Please see our response to all questions in the spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below:  13645 - FOI_9328 - Atopic Dermatitis - FOR ISSUE.xlsx | |
| Question Number 2: In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department 鈥� Abrocitinib 鈥� Baricitinib 鈥� Dupilumab 鈥� Lebrikizumab 鈥� Tralokinumab 鈥� Upadacitinib 鈥� Nemolizumab *Patients are considered 鈥榥ew patients initiated鈥� on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation. e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025) | |
| Answer To Question 2: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 3: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: 鈥� 6 months to 5 鈥� Age 6-11 鈥� Age 12-17 鈥� Age 18 and above | |
| Answer To Question 3: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 4: How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products: 鈥� Dupilumab 鈥� Nemolizumab | |
| Answer To Question 4: Please see our response to all questions in the spreadsheet attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
